Patent ID: 8470340

Claim:
An isolated JAR 4 epitope-containing peptide of at least 9 amino acids in length and comprising the sequence: DX 1 X 2 wherein X 1 is histidine (H) or aspartic acid (D); X 2 is lysine (K) or arginine (R); the aspartic acid residue (D) of the DX 1 X 2 sequence does not contain an N-terminal amino group; the peptide contains at least 3 amino acid residues positioned immediately C-terminal to the X 2 , wherein the at least 3 amino acid residues are selected from: LEGTE, (SEQ ID NO: 1) TGCA, (SEQ ID NO: 2) TQL, AQT, SGC, TANQ, (SEQ ID NO: 3) IWP, HML, and HGF, with the proviso that when the at least 3 amino acid residues are TANQ (SEQ ID NO:3), the peptide comprises a histidine (H) immediately N-terminal to the aspartic acid residue (D) of the DX 1 X 2 sequence, and when the at least 3 amino acid residues are TGCA (SEQ ID NO:2), the peptide comprises a tyrosine (Y) immediately N-terminal to the aspartic acid residue (D) of the DX 1 X 2 sequence; the peptide does not comprise a full-length A domain of a factor H binding protein; and the peptide is specifically bound by JAR 4 monoclonal antibody secreted by the hybridoma deposited as ATCC Accession No. PTA-8943.